GH vs TMO
GH: Guardant Health is a leader in precision oncology, utilizing advanced liquid biopsy technology to provide comprehensive genomic insights across the cancer care continuum. TMO: A massive, diversified life sciences conglomerate providing the essential infrastructure, tools, and services that enable scientific research and global healthcare diagnostics.
Side-by-side fundamentals
| Metric | GH | TMO | Edge |
|---|---|---|---|
| Price as of 2026-10-20 close | $162.59 | $687.37 | |
| Market cap | $21.8B | $254.2B | |
| P/E as of 2026-10-20 | n/a | 37.00 | |
| PEG as of 2026-10-20, 3-year EPS CAGR to FY2025 | n/a | 178.25 | |
| Net margin FY2025, SEC XBRL | -42.4% | +15.0% | TMO higher |
| Operating margin FY2025, SEC XBRL | -44.5% | +17.4% | TMO higher |
| ROE FY2025, SEC XBRL | n/a | +12.6% | |
| ROA FY2025, SEC XBRL | -20.7% | +6.1% | TMO higher |
| Debt / equity filed borrowings, leases excl., balance sheet 2026-06-27 | n/a | 0.87 | |
| Revenue growth (YoY) FY2025, SEC XBRL | +32.9% | +3.9% | GH higher |
| Revenue CAGR (3y) SEC XBRL | +29.8% | -0.3% | GH higher |
| Dividend yield as of 2026-09-02 | n/a | +0.3% | |
| Dividend streak (yrs) SEC XBRL | 0 | 14 | TMO higher |
| Beta as of 2026-09-03 | 1.23 | 0.77 | |
| 1-year return as of 2026-10-20 close | +131.6% | +26.4% | GH higher |
Fundamentals: SEC XBRL company filings for the figures marked with a fiscal year, and market data, as of 2026-09-03 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-20.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.